Key result
The ACCOMPLISH trial is designed to randomize 12,600 hypertensive patients to compare amlodipine/benazapril versus benazapril/hydrochlorothiazide on cardiovascular mortality and morbidity over 5 years.
Why the study?
Does amlodipine/benazapril reduce cardiovascular mortality and morbidity compared to benazapril/hydrochlorothiazide in high-risk hypertensive patients?
Population
12,600 hypertensive patients with risk factors for cardiovascular events
Comparison
Amlodipine/benazapril vs Benazapril/hydrochlorothiazide
Design
Other, randomized, blinded
Follow-up
5 years
Authors
Discussion
Loading...
Member takes
Implication
Supports initial CCB-ACEI combinations in high-risk hypertension; extends evidence favoring this pairing over diuretic-based regimens.
Study Design
Type
RCT (n=12,600)
Blinding
blinded
Randomization
randomized
Multicenter
Yes
Structured PICO
Does amlodipine/benazapril reduce cardiovascular mortality and morbidity compared to benazapril/hydrochlorothiazide in high-risk hypertensive patients?
P
Population
12,600 hypertensive patients with risk factors for cardiovascular events, to be followed for a 5-year period.
I
Intervention
Amlodipine/benazapril (force titrated to 5/40 mg, can be further titrated to 10/40 mg)
C
Comparator
Benazapril/hydrochlorothiazide (force titrated to 40/12.5 mg, can be further titrated to 40/25 mg)
O
Outcome
Composite of cardiovascular mortality and morbiditycomposite
The ACCOMPLISH trial is designed to compare the effects of amlodipine/benazapril versus benazapril/hydrochlorothiazide on cardiovascular outcomes in high-risk hypertensive patients.
Cite This Study
Jamerson et al. (2004) conducted an RCT in Systolic Hypertension (n=12,600). Amlodipine besylate/benazapril vs. Benazapril/hydrochlorothiazide (force titrated to 40/12.5 mg, up to 40/25 mg) was evaluated on Composite of cardiovascular mortality and morbidity. The ACCOMPLISH trial is designed to randomize 12,600 hypertensive patients to compare amlodipine/benazapril versus benazapril/hydrochlorothiazide on cardiovascular mortality and morbidity over 5 years.